{"schema":"sb.node.v1","id":"sb:e/b174577250e03cb43d0c572b","kind":"entity","label":{"text":"breakthrough therapy","locale":"en"},"identity":{"anchor":"label:en:breakthrough therapy","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T23:27:45.667496+00:00","snapshot":"deploy ca5d81785b2e8e9d3cb25b959dbaa72ddee4391e"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":54,"separatePublishers":19,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.148,"named":8,"of":54,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 15% of the 54 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-06-25","to":"2026-10-09","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.5: about 50% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","oncology","fda_decisions","gi_journal"],"activeDays":29,"assertions":{"regulatory-approval":23,"legal-ruling":1,"election":1,"acquisition":1,"military-action":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":3,"byKind":{"observation":3},"withheld":{"state":"withheld","count":3,"reason":"3 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/e5ef8857b699233791fbf5d1","kind":"observation","label":"PR Newswire · 2026-10-07 · AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC","url":"https://www.prnewswire.com/news-releases/abbvies-telisotuzumab-adizutecan-temab-a-receives-two-breakthrough-therapy-designations-from-the-us-fda-for-crc-and-nsclc-302900512.html"},{"id":"sb:o/4168ef4e7155b3e0057081af","kind":"observation","label":"AllSci News · 2026-09-30 · Alume wins FDA Breakthrough Therapy Designation for nerve-visualization agent bevonescein","url":"https://allsci.com/news/regulatory-designations-pathways/fda-breakthrough-therapy-designation-grants-to/"},{"id":"sb:o/b87f0c38ebf2a8fc4ce03811","kind":"observation","label":"The Clinical Trial Vanguard · 2026-09-24 · FDA Approves Lyrfigtu for FGFR2-Rearranged Cholangiocarcinoma","url":"https://www.clinicaltrialvanguard.com/news/fda-approves-lyrfigtu-for-fgfr2-rearranged-cholangiocarcinoma/"}],"cursor":null,"order":"newest first; we keep the 3 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (50 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ea4abce3ca7e6cb1d0ef84fd"},{"kind":"relation","label":"co-mentioned with drug administration (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4c533aeed5af95b749231140"},{"kind":"relation","label":"co-mentioned with orphan drug (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/74c24d87a595a9fd08bf4a20"},{"kind":"relation","label":"co-mentioned with adverse events (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/cea5e9a3c7213eaf08a4858d"},{"kind":"relation","label":"co-mentioned with china (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c087edeb4baec0b7e5704330"},{"kind":"relation","label":"co-mentioned with clinical trials (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9f12da68eccd8b43962a21b8"},{"kind":"relation","label":"co-mentioned with fda-approved (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8c50b07b0789546ec694288d"},{"kind":"relation","label":"co-mentioned with priority review (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a541feff23370c6c4ff5ed2c"},{"kind":"relation","label":"co-mentioned with nasdaq (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/49ce03f84363d3431f818fb7"},{"kind":"relation","label":"co-mentioned with lung cancer (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e1d80fd67127bcdcfa8607c6"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/b174577250e03cb43d0c572b","mcp":"traverse {\"id\":\"sb:e/b174577250e03cb43d0c572b\"}","page":"/entity/breakthrough-therapy/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b174577250e03cb43d0c572b\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b174577250e03cb43d0c572b\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b174577250e03cb43d0c572b\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b174577250e03cb43d0c572b\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}